NR 566 WEEK 4 review Questions with Verified Answers (Correct
Update)
Question 1: In CKD, first-line agents to reduce proteinuria and slow progression are:
Answer: B. ACE inhibitors or ARBs
Question 2: The electrolyte abnormality most responsible for malignant ventricular arrhythmia
risk in
Answer: CKD is: B. Hyperkalemia
Question 3: Which complication of CKD is primarily due to reduced erythropoietin production?
Answer: B. Anemia
Question 4: Uremic pericarditis in CKD results from:
Answer: B. Accumulated nitrogenous wastes
Question 5: The major driver of secondary hyperparathyroidism in CKD is:
Answer: B. Hyperphosphatemia with low calcitriol
Question 6: Sodium handling in CKD is impaired. A common downstream clinical effect is:
Answer: B. Hypertension and edema
Question 7: Appropriate first step when starting epoetin alfa for CKD anemia:
Answer: B. Ensure iron sufficiency and check ferritin and TSAT
Question 8: Black box warning for epoetin alfa includes increased risk of:
Answer: B. Venous thromboembolism, MI, stroke, and death
Question 9: Which is a contraindication to epoetin alfa initiation in CKD?
Answer: B. Uncontrolled hypertension
Question 10: The earliest expected lab change after starting epoetin alfa is:
Answer: B. Reticulocytosis within about 10 days
Question 11: Best counseling for epoetin alfa storage and handling:
Answer: C. Do not shake. Protect from light
Page 1
, Question 12: Sodium polystyrene sulfonate decreases serum potassium primarily by:
Answer: C. Cation exchange in the gut with fecal K+ elimination
Question 13: A serious GI adverse effect associated with SPS is:
Answer: B. Ischemic colitis and colonic necrosis
Question 14: Avoid coadministration of SPS with which agent because of increased colonic injury
risk:
Answer: A. Sorbitol
Question 15: SPS should be avoided in:
Answer: B. Obstructive bowel disease
Question 16: Calcium acetate lowers phosphate by:
Answer: B. Binding dietary phosphate in the gut
Question 17: Key on-therapy risk with calcium acetate in ESRD:
Answer: B. Hypercalcemia and vascular calcification
Question 18: Which drug's absorption can be reduced by calcium acetate binding?
Answer: A. Levothyroxine
Question 19: Dose timing advice for calcium acetate:
Answer: B. Take with meals
Question 20: Cinacalcet mechanism of action is best described as:
Answer: B. Calcimimetic increasing CaSR sensitivity to Ca
Question 21: The most common adverse effect with cinacalcet is:
Answer: B. Nausea and vomiting
Question 22: Absolute contraindication for cinacalcet:
Answer: A. Severe hypocalcemia
Question 23: Key interaction that raises cinacalcet levels:
Answer: B. Ketoconazole
Page 2
Update)
Question 1: In CKD, first-line agents to reduce proteinuria and slow progression are:
Answer: B. ACE inhibitors or ARBs
Question 2: The electrolyte abnormality most responsible for malignant ventricular arrhythmia
risk in
Answer: CKD is: B. Hyperkalemia
Question 3: Which complication of CKD is primarily due to reduced erythropoietin production?
Answer: B. Anemia
Question 4: Uremic pericarditis in CKD results from:
Answer: B. Accumulated nitrogenous wastes
Question 5: The major driver of secondary hyperparathyroidism in CKD is:
Answer: B. Hyperphosphatemia with low calcitriol
Question 6: Sodium handling in CKD is impaired. A common downstream clinical effect is:
Answer: B. Hypertension and edema
Question 7: Appropriate first step when starting epoetin alfa for CKD anemia:
Answer: B. Ensure iron sufficiency and check ferritin and TSAT
Question 8: Black box warning for epoetin alfa includes increased risk of:
Answer: B. Venous thromboembolism, MI, stroke, and death
Question 9: Which is a contraindication to epoetin alfa initiation in CKD?
Answer: B. Uncontrolled hypertension
Question 10: The earliest expected lab change after starting epoetin alfa is:
Answer: B. Reticulocytosis within about 10 days
Question 11: Best counseling for epoetin alfa storage and handling:
Answer: C. Do not shake. Protect from light
Page 1
, Question 12: Sodium polystyrene sulfonate decreases serum potassium primarily by:
Answer: C. Cation exchange in the gut with fecal K+ elimination
Question 13: A serious GI adverse effect associated with SPS is:
Answer: B. Ischemic colitis and colonic necrosis
Question 14: Avoid coadministration of SPS with which agent because of increased colonic injury
risk:
Answer: A. Sorbitol
Question 15: SPS should be avoided in:
Answer: B. Obstructive bowel disease
Question 16: Calcium acetate lowers phosphate by:
Answer: B. Binding dietary phosphate in the gut
Question 17: Key on-therapy risk with calcium acetate in ESRD:
Answer: B. Hypercalcemia and vascular calcification
Question 18: Which drug's absorption can be reduced by calcium acetate binding?
Answer: A. Levothyroxine
Question 19: Dose timing advice for calcium acetate:
Answer: B. Take with meals
Question 20: Cinacalcet mechanism of action is best described as:
Answer: B. Calcimimetic increasing CaSR sensitivity to Ca
Question 21: The most common adverse effect with cinacalcet is:
Answer: B. Nausea and vomiting
Question 22: Absolute contraindication for cinacalcet:
Answer: A. Severe hypocalcemia
Question 23: Key interaction that raises cinacalcet levels:
Answer: B. Ketoconazole
Page 2
